Genelux (GNLX) to Post Earnings on Thursday

Genelux (NASDAQ:GNLX) is projected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Genelux to post earnings of ($0.20) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:00 PM ET.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). On average, analysts expect Genelux to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Genelux Trading Down 3.1%

Shares of NASDAQ GNLX opened at $2.83 on Thursday. Genelux has a 12 month low of $2.29 and a 12 month high of $8.53. The firm has a market capitalization of $126.90 million, a PE ratio of -3.33 and a beta of 0.58. The firm has a fifty day simple moving average of $2.95 and a two-hundred day simple moving average of $2.77.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on GNLX. Wall Street Zen cut shares of Genelux from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Genelux in a report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Insider Activity

In other news, Director John W. Smither sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $2.91, for a total value of $34,920.00. Following the sale, the director directly owned 91,403 shares of the company’s stock, valued at $265,982.73. The trade was a 11.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director John Thomas sold 10,000 shares of Genelux stock in a transaction on Monday, June 1st. The shares were sold at an average price of $2.98, for a total value of $29,800.00. Following the transaction, the director owned 472,784 shares of the company’s stock, valued at $1,408,896.32. The trade was a 2.07% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,865 shares of company stock worth $76,110 in the last three months. 7.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Genelux

A number of hedge funds have recently bought and sold shares of the company. Marshall Wace LLP increased its stake in Genelux by 312.3% during the 4th quarter. Marshall Wace LLP now owns 139,148 shares of the company’s stock valued at $607,000 after purchasing an additional 105,402 shares in the last quarter. LPL Financial LLC lifted its stake in shares of Genelux by 22.4% in the fourth quarter. LPL Financial LLC now owns 134,357 shares of the company’s stock worth $586,000 after buying an additional 24,580 shares in the last quarter. 683 Capital Management LLC bought a new position in shares of Genelux in the fourth quarter worth approximately $572,000. Millennium Management LLC purchased a new stake in Genelux during the 4th quarter valued at $455,000. Finally, Barclays PLC purchased a new stake in Genelux during the 4th quarter valued at $360,000. Institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.